Interim FDG-PET/CT for Response Assessment of Lymphoma

Area of Science:

• Oncology
• Nuclear Medicine
• Radiology

Background:

• Interim FDG-PET/CT (iPET/CT) is used during lymphoma treatment.
• Its prognostic value and clinical utility differ across lymphoma subtypes.

Purpose of the Study:

• To review evidence on iPET/CT's prognostic value in lymphoma.
• To discuss its role in guiding response-adapted treatment strategies.

Main Methods:

• Review of clinical evidence and major clinical trials.
• Focus on classical Hodgkin lymphoma (cHL) and specific non-Hodgkin lymphoma (NHL) subtypes (DLBCL, FL, PTCL).

Main Results:

• Robust evidence supports iPET/CT prognostication in cHL, enabling standard-of-care response-adapted therapy.
• In NHL, a complete metabolic response on iPET/CT is generally favorable; lack of response indicates poor prognosis.

Conclusions:

• iPET/CT is a valuable tool for prognostication and tailoring lymphoma treatment.
• Its application is well-established in cHL and emerging in specific NHL subtypes.